BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan LK, Ho DW, Kam CS, Chiu EY, Lo IL, Yau DT, Cheung ET, Tang CN, Tang VW, Lee TK, Wong CC, Chok KS, Chan AC, Cheung TT, Wong CM, Ng IO. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol 2021;74:360-71. [PMID: 32918955 DOI: 10.1016/j.jhep.2020.08.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Wang M, Zhang M, Xu K, Zhang X, Xie Y, Zhang Y, Chang C, Li X, Sun A, He F. High-affinity SOAT1 ligands remodeled cholesterol metabolism program to inhibit tumor growth. BMC Med 2022;20:292. [PMID: 35941608 DOI: 10.1186/s12916-022-02436-8] [Reference Citation Analysis]
2 Laka K, Makgoo L, Mbita Z. Cholesterol-Lowering Phytochemicals: Targeting the Mevalonate Pathway for Anticancer Interventions. Front Genet 2022;13:841639. [DOI: 10.3389/fgene.2022.841639] [Reference Citation Analysis]
3 Liu W, Deng Y, Li Z, Chen Y, Zhu X, Tan X, Cao G. Cancer Evo-Dev: A Theory of Inflammation-Induced Oncogenesis. Front Immunol 2021;12:768098. [PMID: 34880864 DOI: 10.3389/fimmu.2021.768098] [Reference Citation Analysis]
4 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cable J, Pei D, Reid LM, Wang XW, Bhatia S, Karras P, Melenhorst JJ, Grompe M, Lathia JD, Song E, Kuo CJ, Zhang N, White RM, Ma SK, Ma L, Chin YR, Shen MM, Ng IOL, Kaestner KH, Zhou L, Sikandar S, Schmitt CA, Guo W, Wong CC, Ji J, Tang DG, Dubrovska A, Yang C, Wiedemeyer WR, Weissman IL. Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. Ann N Y Acad Sci 2021;1506:142-63. [PMID: 34850398 DOI: 10.1111/nyas.14719] [Reference Citation Analysis]
6 Kumar N, Mandal CC. Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis. Front Genet 2021;12:724149. [PMID: 34603386 DOI: 10.3389/fgene.2021.724149] [Reference Citation Analysis]
7 Zhao Y, Chen R, Deng Z, Zhang L, Cheng Y, Chen AF, Cao D. Discovery of novel p90 ribosomal S6 kinase 2 inhibitors for potential cancer treatment through ligand-based and structure-based virtual screening methods. Chemometrics and Intelligent Laboratory Systems 2021;217:104402. [DOI: 10.1016/j.chemolab.2021.104402] [Reference Citation Analysis]
8 Yuan L, Wu XJ, Li WC, Zhuo C, Xu Z, Tan C, Ma R, Wang J, Pu J. SLC6A8 Knockdown Suppresses the Invasion and Migration of Human Hepatocellular Carcinoma Huh-7 and Hep3B Cells. Technol Cancer Res Treat 2020;19:1533033820983029. [PMID: 33356959 DOI: 10.1177/1533033820983029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lee JS, Kim HY, Won B, Kang SW, Kim YN, Jang H. SEZ6L2 Is an Important Regulator of Drug-Resistant Cells and Tumor Spheroid Cells in Lung Adenocarcinoma. Biomedicines 2020;8:E500. [PMID: 33202873 DOI: 10.3390/biomedicines8110500] [Reference Citation Analysis]